Tralokinumab-ldrm (Adbry, LEO Pharma Inc.) is now available as a 300mg/2mL single-dose autoinjector in the United States.
Tralokinumab-ldrm is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Prior to the introduction of the autoinjector device, tralokinumab-ldrm was only available in a 150mg/1mL pre-filled syringe. With the new 300 mg/2 mL autoinjector device, adult patients now have another option and half the number of required injections compared to the 150mg/ mL pre-filled syringe.
“I understand from discussions with my patients that living with AD already brings a wide range of difficulties and debilitating factors that need to be managed on a daily basis, so it is integral that any treatment solution is more convenient to manage for those living with the condition, and does not add even more of a burden,” says Jonathan Silverberg, M.D., Ph.D., Professor of Dermatology, of George Washington University in Washington, DC, in a news release. “This new administration option reduces the number of injections required overall and provides adults living with AD with an additional option in how they manage their condition.”
For patients who prefer the pre-filled syringe, this option will continue to be available in the U.S. for both adults and pediatric patients (age 12-17).
In the U.S., tralokinumab-ldrm is available in a 150mg/1mL single-use pre-filled syringe as well as a 300mg/2mL single-use autoinjector. For adults, tralokinumab-ldrm is administered with an initial loading dose of 600mg (four injections with prefilled syringe or two injections with autoinjector) followed by a maintenance dose of 300mg dose every two weeks (two injections with prefilled syringe or one injection with the autoinjector). Tralokinumab-ldrm adult patients have the flexibility to take a single monthly dose (300 mg/2 mL every 4 weeks) for those who achieve clear or almost clear skin after 16 weeks and weigh<220 pounds.
Tralokinumab-ldrm is marketed outside of the U.S. under the tradename Adtralza (tralokinumab) and is approved for the treatment of adults and pediatric patients (12 years and above) with moderate-to- severe AD in the U.S., Canada, the European Union, the United Arab Emirates, Great Britain, Saudi Arabia and South Korea. Adtralza is approved for use in adults with moderate-to-severe AD in Switzerland, and Japan.
